(Corrects drug descriptor in headline and paragraph one)

June 20 (Reuters) - U.S. health regulators informed Pozen Inc that they have come to a preliminary determination that the company's experimental drug to prevent stomach ulcers related to aspirin use did not show bioequivalence with 325 mg aspirin, further jeopardizing the drug's chances to win approval soon.